This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck's Pneumococcal Vaccine Meets Goal in Two Adult Studies
by Zacks Equity Research
Merck's (MRK) development program on V114 comprises 16 studies, evaluating safety, tolerability and immunogenicity of V114 in a variety of patient populations.
Pfizer Begins Four Phase III Studies on Vaccine Candidates
by Zacks Equity Research
Pfizer (PFE) begins four phase III studies on vaccine candidates. EMA validates its label expansion application for Bavencio in first-line bladder cancer.
Sarepta Inks Agreement With Codiak to Develop Gene Therapies
by Zacks Equity Research
Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.
Mylan Gets Favorable Ruling Against Biogen's Tecfidera Patent
by Zacks Equity Research
Mylan (MYL) wins the district court's decision against Biogen's lead MS drug's patent.
Merck's Keytruda Gets Accelerated Approval for Solid Tumors
by Zacks Equity Research
Merck's (MRK) sBLA seeking approval of Keytruda for advanced solid tumors, based on biomarker, regardless of tumor type, gets FDA's accelerated approval.
Merck's Steglatro Non-Inferior in Cardiovascular Outcomes Study
by Zacks Equity Research
Merck's (MRK) type 2 diabetes drug, Steglatro, achieves primary endpoint of non-inferiority in major adverse CV events compared to placebo in a late-stage cardiovascular outcomes study.
Lilly Gains as Verzenio Meets Early Breast Cancer Study Goal
by Zacks Equity Research
Lilly's (LLY) phase III study on Verzenio in HR+, HER2- early breast cancer met its primary endpoint of invasive disease-free survival.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $33.36 in the latest trading session, marking a -1.16% move from the prior day.
Glaxo (GSK) HIV Drug Tivicay Gets FDA Approval for Toddlers
by Zacks Equity Research
FDA approves Glaxo's (GSK) oral suspension formulation of its three-drug regimen for HIV, Tivicay, as a treatment for patients aged at least four weeks and weighing at least 3kg.
AstraZeneca to Supply 400M Coronavirus Vaccine Doses in Europe
by Zacks Equity Research
AstraZeneca's (AZN) supply deals will require it to produce 2 billion doses of the vaccine, if it is successfully developed.
Mylan & Biocon's Semglee Wins FDA Approval for Diabetes
by Zacks Equity Research
Mylan (MYL) and partner Biocon gains FDA approval for diabetes treatment, Semglee.
Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals
by Kinjel Shah
J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.
Pfizer's Eczema Candidate Meets All Goals in Study on Teens
by Zacks Equity Research
Pfizer's (PFE) investigational eczema treatment, abrocitinib, succeeds in a late-stage study under the JADE program in patients aged 12 years and above.
J&J to Begin Human Study on Coronavirus Vaccine in July
by Zacks Equity Research
J&J's (JNJ) goal is to supply more than 1 billion doses of the vaccine globally if it proves to be safe and effective.
Merck's Keytruda Fails in First-Line Bladder Cancer Study
by Zacks Equity Research
Merck's (MRK) phase III advanced bladder cancer study on Keytruda fails to meet dual primary endpoints of overall survival (OS) or progression-free survival (PFS).
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $36.21, moving -1.04% from the previous trading session.
Sarepta's Gene Therapy Promising in Muscular Dystrophy Study
by Zacks Equity Research
Sarepta's (SRPT) gene therapy candidate for treating limb-girdle muscular dystrophy shows continued functional improvement over a year for the lower dose as well as increasing efficacy with higher dose.
Gilead Up on Report of AstraZeneca's Interest in Merger
by Zacks Equity Research
Gilead (GILD) gains after report surfaces that AstraZeneca has shown interest in the former last month.
Lilly's 2nd Potential Coronavirus Antibody Candidate in Phase I
by Zacks Equity Research
Lilly (LLY) is set to study JS016 as a monotherapy and in combination with antibody treatments including LY-CoV555, its first potential COVID-19 antibody candidate that recently entered phase I.
Drugmakers Target Coronavirus Vaccine in 2020: 4 Stocks in Focus
by Ritujay Ghosh
Several drugmakers have started ramping up production, anticipating huge demand if the candidates prove successful.
Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.
Trump Picks 5 Coronavirus Vaccine Candidates Per NYT Report
by Kinjel Shah
The candidates belong to five companies, Moderna, AstraZeneca, J&J, Merck and Pfizer.
The Zacks Analyst Blog Highlights: Pfizer, Comcast, salesforce.com, Costco Wholesale and BHP Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Comcast, salesforce.com, Costco Wholesale and BHP Group
Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.
The Zacks Analyst Blog Highlights: Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer